FMS-like tyrosine kinase 3 (FLT3) mutations are common in patients with acute myeloid leukemia (AML), and is often associated with a poor prognosis. Despite the development of FLT3 inhibitors such as midostaurin, sorafenib, and qauizartinib, patients often progress on these therapies due to secondary mutations. Various strategies to improve patient outcomes such novel combinations with other agents including hypomethylating agents or venetoclax are currently under investigation.
In this podcast, Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, and Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, have an insightful discussion on FLT3-mutated acute myeloid leukemia (AML) updates presented at the ASH 2021 annual meeting. They give an overview of the use of FLT3 inhibitors in combination with other agents, as well as trial data from the LACEWING trial (NCT02752035) of gilteritinib in combination with azacitidine in the frontline setting.
This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
The growing role of immunotherapy in the treatment of ALL & moving away from stem cell transplantation
The current status of CAR-T therapy in CLL and challenges in this space
Managing and treating GvHD and other post-transplant complications
The role of MRD in multiple myeloma
Novel immune therapies in MDS and challenges in this space
NHL highlights at ASH 2022: Updates in MCL, the role of transplantation, and novel bispecific antibodies
MPN highlights at ASH 2022: Novel agents, combinations & the role of immunotherapy
T-cell lymphoma highlights at ASH 2022: Unmet needs, clinical trial updates & future outlooks
The importance of CD47 in MDS and other targets of interest
CLL highlights at ASH 2022: Clinical trial updates, novel BTK inhibitors & combination therapy
Myeloma highlights at ASH 2022: Improving access to CAR-T therapy & future outlooks
Highlights in MDS at ASH 2022: Treating lower-risk & higher-risk disease, trial updates, & more
iwNHL Session V: Novel therapies in NHL - the role of ADCs
iwAL 2022 Session V: Mechanisms of resistance to targeted therapies in AML
The importance of genomic testing in CLL and its role in clinical decision-making
iwNHL Session IV: T-cell therapies for NHL: CAR-T therapies & third-party EBV T-cells
Key updates in CLL: novel treatment strategies, the changing role of chemotherapy, and more
iwAL 2022 Session IV: The evolving treatment landscape in ALL and the growing role of immunotherapies
iwNHL Session III: Exploring the optimal management of R/R follicular lymphoma in an expanding treatment landscape
iwAL 2022 Session III: Novel targets, combinations and treatment strategies in AML
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Peter Attia Drive
The Doctor’s Farmacy with Mark Hyman, M.D.